Epidermal Nerve Fiber Density, Fat and Mitochondrial Parameters in Thai HIV+ Patients on d4T and HIV- Patients
NCT01178684 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113
Last updated 2014-09-26
Summary
This study will provide the range of Epidermal Nerve Fiber Density (ENFD) typically seen in Thai individuals. ENFD values from Thai HIV-negative subjects without neuropathy will be used as appropriate reference norm for Thai HIV-positive subjects. In particular, comparison of ENFD values from Thai HIV-negative subjects with baseline ENFD values in Thai HIV-positive subjects prior to highly active antiretroviral therapy (HAART) will allow examination of the effect of HIV per se on ENFD. ENFD from Thai HIV-positive subjects on long-term d4T (stavudine) with and without neuropathy will also provide reference ENFD values at the extremes of the disease process i.e. extent of ENFD decrease in subjects with d4T-induced symptomatic neuropathy and in subjects completely free of disease despite d4T treatment for comparison with Thai HIV-positive subjects on short-term d4T in SEARCH 003 study.
Conditions
Sponsors & Collaborators
-
University of Hawaii
collaborator OTHER -
SEARCH Research Foundation
lead OTHER
Principal Investigators
-
Jintanat Ananworanich, MD, PhD · SEARCH Research Foundation
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2012-11-30
- Completion
- 2012-12-31
Countries
- Thailand
Study Locations
More Related Trials
-
A Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infection
NCT01296373 ·Status: COMPLETED
-
A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine
NCT01159743 ·Status: COMPLETED
-
PREventing Progression of Adipose Tissue Redistribution
NCT00389194 ·Status: COMPLETED ·Phase: PHASE4
-
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
NCT00126308 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE
NCT00383734 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
NCT00005764 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity
NCT01044810 ·Status: COMPLETED
-
A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects
NCT01850212 ·Status: COMPLETED
-
Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation
NCT02771054 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
NCT02582983 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
NCT00122655 ·Status: TERMINATED ·Phase: PHASE4
-
Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada
NCT00324649 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
NCT01709084 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
NCT05898841 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy
NCT00312832 ·Status: COMPLETED ·Phase: NA
-
Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
NCT00646984 ·Status: COMPLETED ·Phase: PHASE4
-
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
NCT02121795 ·Status: COMPLETED ·Phase: PHASE3
-
Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation
NCT01138241 ·Status: COMPLETED
-
A Study of CL-197 Capsules in Healthy Participants
NCT05944848 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
NCT04442737 ·Status: COMPLETED ·Phase: PHASE4
-
Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
NCT00270556 ·Status: COMPLETED ·Phase: PHASE2
-
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
NCT00100984 ·Status: TERMINATED ·Phase: PHASE4
-
Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD
NCT04311944 ·Status: UNKNOWN ·Phase: NA
-
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
NCT02616029 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV
NCT00122512 ·Status: TERMINATED ·Phase: PHASE2